Pharmacotherapy prescribing pattern and outcome for hospitalized patients with severe and critical COVID-19
Hayder Assad
Current Issues in Pharmacy and Medical Sciences, doi:10.2478/cipms-2022-0020
INTRODUCTION Coronavirus Disease 2019 (COVID-19) is a pandemic disease originating in late 2019 in the People's Republic of China that spread rapidly worldwide [1]. The first reported case in the Najaf governorate, Iraq, was confirmed on February 24, 2020 [2]. As of early June 2021, the global reported cases of COVID-19 have exceeded 170 million with over 3 million deaths [3]. The clinical spectrum of this illness ranges from asymptomatic infection, to acute respiratory distress syndrome (ARDS), circulatory shock, multiorgan failure, and ultimately death [4] . The death rate related to COVID-19 is relatively high -ranging from 5% to 35%, especially in elderly patients and those who have comorbidities [5] . Although different treatment strategies have been explored and used based on emergency approval and evidence-based
ORCID iDs Hayder Assad https://orcid.org/0000-0003-3499-3007
References
Alsharidah, Ayed, Ameen, Alhuraish, Rouheldeen et al., COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study, Int J Infect Dis
Arshad, Kilgore, Chaudhry, Jacobsen, Wang et al., Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int J Infect Dis
Bajwah, Wilcock, Towers, Costantini, Bausewein et al., Managing the supportive care needs of those affected by COVID-19, Eur Respir J
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of COVID-19 -Final Report, N Engl J Med
Best, Kong, Kaplan-Lewis, Brawley, Baden et al., Treatment patterns in US patients hospitalized with COVID-19 and pulmonary involvement, J Med Virol
Campos Dm De, Fulco, De Oliveira, Oliveira, SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies, J Evid Based Med
Chappell, Horby, Lim, Emberson, Mafham et al., Dexamethasone in hospitalized patients with COVID-19 -preliminary report, N Engl J Med
Chibber, Haq, Ahmed, Andrabi, Singh, Advances in the possible treatment of COVID-19: A review, Eur J Pharmacol
Freedberg, Conigliaro, Wang, Tracey, Callahan et al., Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study, Gastroenterol
Kewan, Covut, Mj, Rose, Gopalakrishna et al., Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study, E Clinical Medicine
Lin, Schneeweiss, Tesfaye, Andrea, Liu et al., Pharmacotherapy for hospitalized patients with COVID-19: Treatment patterns by disease severity, Drugs
Mk, Ma, Incidence of the COVID-19 in Iraq -Implications for travellers, Travel Med Infect Dis
Padhy, Mohanty, Das, Meher, Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis, J Pharm Pharm Sci
Phelan, Katz, Lo, The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance, JAMA
Rattanaumpawan, Jirajariyavej, Lerdlamyong, Palavutitotai, Saiyarin, Real-world experience with favipiravir for treatment of COVID-19 in Thailand: Results from a multi-center observational study,
doi:10.1101/2020.06.24.20133249Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA
Sahebnasagh, Avan, Saghafi, Mojtahedzadeh, Sadremomtaz et al., Pharmacological treatments of COVID-19, Pharmacol Rep
Salazar, Christensen, Graviss, Nguyen, Castillo et al., Treatment of Coronavirus Disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality, Am J Pathol
Sanders, Monogue, Jodlowski, Cutrell, Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19): A review, JAMA
Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA
Wang, Zhang, Du, Du, Zhao et al., Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebocontrolled, multicentre trial, Lancet
Watanabe, Kwon, Abeles, Jia, Mehta, Medication use patterns in hospitalized patients with COVID-19 in California During the pandemic, JAMA Netw Open
Who, None
Who, None
Zanasi, Mazzolini, Kantar, A reappraisal of the mucoactive activity and clinical efficacy of bromhexine, Multidiscip Respir Med
DOI record:
{
"DOI": "10.2478/cipms-2022-0020",
"ISSN": [
"2300-6676"
],
"URL": "http://dx.doi.org/10.2478/cipms-2022-0020",
"abstract": "<jats:title>Abstract</jats:title>\n <jats:p>There are many treatment modalities for COVID-19 – with varied outcome. Therefore, authors designed this study to assess prescribing patterns and the clinical outcome for hospitalized patients with severe and critical COVID-19 so as to determine the most effective approach.</jats:p>\n <jats:p>Authors conducted a retrospective observational study on 346 adult patients with either severe or critical COVID-19, who were admitted to public hospitals in Al-Najaf city, Iraq from June to September 2020. Patients’ information, medications and outcomes were collected from their medical records in the registered office of the hospital.</jats:p>\n <jats:p>A total of 346 patients were enrolled, with a majority of patients being adults above 35 years old and male (70.2%). Most patients (81%) received corticosteroid as dexamethasone, and about 45% of all patients were given convalescent plasma therapy, while a few patients were prescribed antiviral favipiravir (23%) and lopinavir/ritonavir (19%). As supportive care medications, anticoagulant such as enoxaparin was administered to most of the patients (93%) and more than half of all patients received the broad-spectrum antibiotic, meropenem.</jats:p>\n <jats:p>The majority of the patients recovered and were discharged alive (66%), however, the in- hospital mortality rate was 26%. Interestingly, patients treated with enoxaparin alone or in combination with hydroxychloroquine were associated with better outcome.</jats:p>\n <jats:p>The prescribing pattern of COVID-19 specific medications and supportive care is aligned with guideline recommendations and associated with a beneficial therapeutic outcome.</jats:p>",
"alternative-id": [
"10.2478/cipms-2022-0020"
],
"author": [
{
"ORCID": "http://orcid.org/0000-0003-3499-3007",
"affiliation": [
{
"name": "Department of Clinical Pharmacy, Faculty of Pharmacy , University of Kufa , Najaf , Iraq"
}
],
"authenticated-orcid": false,
"family": "Assad",
"given": "Hayder",
"sequence": "first"
}
],
"container-title": "Current Issues in Pharmacy and Medical Sciences",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2022,
10,
21
]
],
"date-time": "2022-10-21T13:20:19Z",
"timestamp": 1666358419000
},
"deposited": {
"date-parts": [
[
2022,
10,
22
]
],
"date-time": "2022-10-22T03:23:54Z",
"timestamp": 1666409034000
},
"indexed": {
"date-parts": [
[
2022,
10,
23
]
],
"date-time": "2022-10-23T05:01:56Z",
"timestamp": 1666501316838
},
"is-referenced-by-count": 0,
"issue": "0",
"issued": {
"date-parts": [
[
2022,
10,
21
]
]
},
"journal-issue": {
"issue": "0",
"published-online": {
"date-parts": [
[
2022,
10,
21
]
]
}
},
"language": "en",
"license": [
{
"URL": "http://creativecommons.org/licenses/by-nc-nd/3.0",
"content-version": "unspecified",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2022,
10,
21
]
],
"date-time": "2022-10-21T00:00:00Z",
"timestamp": 1666310400000
}
}
],
"link": [
{
"URL": "https://www.sciendo.com/pdf/10.2478/cipms-2022-0020",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "374",
"original-title": [],
"prefix": "10.2478",
"published": {
"date-parts": [
[
2022,
10,
21
]
]
},
"published-online": {
"date-parts": [
[
2022,
10,
21
]
]
},
"publisher": "Walter de Gruyter GmbH",
"reference": [
{
"DOI": "10.1001/jama.2020.1097",
"doi-asserted-by": "crossref",
"key": "2022102203230152355_j_cipms-2022-0020_ref_001",
"unstructured": "1. Phelan AL, Katz R, Gostin LO. The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. JAMA. 2020;323(8):709-10.10.1001/jama.2020.109731999307"
},
{
"DOI": "10.1016/j.tmaid.2020.101739",
"doi-asserted-by": "crossref",
"key": "2022102203230152355_j_cipms-2022-0020_ref_002",
"unstructured": "2. Al-Malkey MK, Al-Sammak MA. Incidence of the COVID-19 in Iraq – Implications for travellers. Travel Med Infect Dis. 2020;38:101739.10.1016/j.tmaid.2020.101739721936332405265"
},
{
"key": "2022102203230152355_j_cipms-2022-0020_ref_003",
"unstructured": "3. WHO; 2021. [https://covid19.who.int/] (access: 04 June 2021)"
},
{
"DOI": "10.1001/jama.2020.1585",
"doi-asserted-by": "crossref",
"key": "2022102203230152355_j_cipms-2022-0020_ref_004",
"unstructured": "4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9.10.1001/jama.2020.1585704288132031570"
},
{
"DOI": "10.1001/jama.2020.6775",
"doi-asserted-by": "crossref",
"key": "2022102203230152355_j_cipms-2022-0020_ref_005",
"unstructured": "5. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-9.10.1001/jama.2020.6775717762932320003"
},
{
"DOI": "10.1001/jama.2020.6019",
"doi-asserted-by": "crossref",
"key": "2022102203230152355_j_cipms-2022-0020_ref_006",
"unstructured": "6. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19): A review. JAMA. 2020;323(18):1824-36.10.1001/jama.2020.601932282022"
},
{
"DOI": "10.1183/13993003.00815-2020",
"doi-asserted-by": "crossref",
"key": "2022102203230152355_j_cipms-2022-0020_ref_007",
"unstructured": "7. Bajwah S, Wilcock A, Towers R, Costantini M, Bausewein C, Simon ST, et al. Managing the supportive care needs of those affected by COVID-19. Eur Respir J. 2020;55(4):2000815.10.1183/13993003.00815-2020714426832269090"
},
{
"DOI": "10.1111/jebm.12414",
"doi-asserted-by": "crossref",
"key": "2022102203230152355_j_cipms-2022-0020_ref_008",
"unstructured": "8. Campos DM de O, Fulco UL, de Oliveira CBS, Oliveira JIN. SARSCoV-2 virus infection: Targets and antiviral pharmacological strategies. J Evid Based Med. 2020;13(4):255-60.10.1111/jebm.12414767531533058394"
},
{
"DOI": "10.1007/s43440-020-00152-9",
"doi-asserted-by": "crossref",
"key": "2022102203230152355_j_cipms-2022-0020_ref_009",
"unstructured": "9. Sahebnasagh A, Avan R, Saghafi F, Mojtahedzadeh M, Sadremomtaz A, Arasteh O, et al. Pharmacological treatments of COVID-19. Pharmacol Rep. 2020;72:1446-78.10.1007/s43440-020-00152-9743963932816200"
},
{
"DOI": "10.1056/NEJMoa2021436",
"doi-asserted-by": "crossref",
"key": "2022102203230152355_j_cipms-2022-0020_ref_010",
"unstructured": "10. Chappell L, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with COVID-19 – preliminary report. N Engl J Med. 2021;384(8):693-704.10.1056/NEJMoa2021436738359532678530"
},
{
"DOI": "10.1016/j.eclinm.2020.100418",
"doi-asserted-by": "crossref",
"key": "2022102203230152355_j_cipms-2022-0020_ref_011",
"unstructured": "11. Kewan T, Covut F, Al-Jaghbeer MJ, Rose L, Gopalakrishna KV, Akbik B. Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study. E Clinical Medicine. 2020;24:100418.10.1016/j.eclinm.2020.100418730550532766537"
},
{
"key": "2022102203230152355_j_cipms-2022-0020_ref_012",
"unstructured": "12. WHO; 2021.[https://www.who.int/] (access: 28 June 2021)"
},
{
"DOI": "10.1002/jmv.27049",
"doi-asserted-by": "crossref",
"key": "2022102203230152355_j_cipms-2022-0020_ref_013",
"unstructured": "13. Best JH, Kong AM, Kaplan-Lewis E, Brawley OW, Baden R, Zazzali JL, et al. Treatment patterns in US patients hospitalized with COVID-19 and pulmonary involvement. J Med Virol. 2021;93:5367-75.10.1002/jmv.27049"
},
{
"DOI": "10.1016/j.ejphar.2020.173372",
"doi-asserted-by": "crossref",
"key": "2022102203230152355_j_cipms-2022-0020_ref_014",
"unstructured": "14. Chibber P, Haq SA, Ahmed I, Andrabi NI, Singh G. Advances in the possible treatment of COVID-19: A review. Eur J Pharmacol. 2020;883:173372.10.1016/j.ejphar.2020.173372"
},
{
"DOI": "10.1007/s40265-020-01424-7",
"doi-asserted-by": "crossref",
"key": "2022102203230152355_j_cipms-2022-0020_ref_015",
"unstructured": "15. Lin KJ, Schneeweiss S, Tesfaye H, D’Andrea E, Liu J, Lii J, et al. Pharmacotherapy for hospitalized patients with COVID-19: Treatment patterns by disease severity. Drugs. 2020;80(18):1961-72.10.1007/s40265-020-01424-7"
},
{
"key": "2022102203230152355_j_cipms-2022-0020_ref_016",
"unstructured": "16. Centers for Disease Control and Prevention. Guidance for COVID-19. [https://www.cdc.gov/coronavirus/2019-ncov/communication/guidance.html] (access: 27 June 0 2021)."
},
{
"DOI": "10.1001/jamanetworkopen.2021.10775",
"doi-asserted-by": "crossref",
"key": "2022102203230152355_j_cipms-2022-0020_ref_017",
"unstructured": "17. Watanabe JH, Kwon J, Nan B, Abeles SR, Jia S, Mehta SR. Medication use patterns in hospitalized patients with COVID-19 in California During the pandemic. JAMA Netw Open. 2021;4(5):e2110775.10.1001/jamanetworkopen.2021.10775"
},
{
"DOI": "10.1056/NEJMoa2007764",
"doi-asserted-by": "crossref",
"key": "2022102203230152355_j_cipms-2022-0020_ref_018",
"unstructured": "18. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19 – Final Report. N Engl J Med. 2020;383(19):1813-26.10.1056/NEJMoa2007764"
},
{
"key": "2022102203230152355_j_cipms-2022-0020_ref_019",
"unstructured": "19. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-78.10.1016/S0140-6736(20)31022-9"
},
{
"DOI": "10.1101/2020.06.24.20133249",
"doi-asserted-by": "crossref",
"key": "2022102203230152355_j_cipms-2022-0020_ref_020",
"unstructured": "20. Rattanaumpawan P, Jirajariyavej S, Lerdlamyong K, Palavutitotai N, Saiyarin J. Real-world experience with favipiravir for treatment of COVID-19 in Thailand: Results from a multi-center observational study. MedRxiv. 2020. [https://doi.org/10.1101/2020.06.24.20133249]10.1101/2020.06.24.20133249"
},
{
"DOI": "10.1016/j.ajpath.2020.08.001",
"doi-asserted-by": "crossref",
"key": "2022102203230152355_j_cipms-2022-0020_ref_021",
"unstructured": "21. Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, et al. Treatment of Coronavirus Disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am J Pathol. 2020;190(11):2290-303.10.1016/j.ajpath.2020.08.001741790132795424"
},
{
"DOI": "10.1016/j.ijid.2020.11.198",
"doi-asserted-by": "crossref",
"key": "2022102203230152355_j_cipms-2022-0020_ref_022",
"unstructured": "22. Alsharidah S, Ayed M, Ameen RM, Alhuraish F, Rouheldeen NA, Alshammari FR, et al. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study. Int J Infect Dis. 2021;103:439-46.10.1016/j.ijid.2020.11.198771777233285283"
},
{
"DOI": "10.1016/j.ijid.2020.06.099",
"doi-asserted-by": "crossref",
"key": "2022102203230152355_j_cipms-2022-0020_ref_023",
"unstructured": "23. Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020;97:396-403.10.1016/j.ijid.2020.06.099733057432623082"
},
{
"DOI": "10.1053/j.gastro.2020.05.053",
"doi-asserted-by": "crossref",
"key": "2022102203230152355_j_cipms-2022-0020_ref_024",
"unstructured": "24. Freedberg DE, Conigliaro J, Wang TC, Tracey KJ, Callahan MV, Abrams JA, et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. Gastroenterol. 2020;159(3):1129-31.e3.10.1053/j.gastro.2020.05.053724219132446698"
},
{
"DOI": "10.18433/jpps31457",
"doi-asserted-by": "crossref",
"key": "2022102203230152355_j_cipms-2022-0020_ref_025",
"unstructured": "25. Padhy BM, Mohanty RR, Das S, Meher BR. Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis. J Pharm Pharm Sci. 2020;23:462-9.10.18433/jpps3145733227231"
},
{
"DOI": "10.1186/s40248-017-0088-1",
"doi-asserted-by": "crossref",
"key": "2022102203230152355_j_cipms-2022-0020_ref_026",
"unstructured": "26. Zanasi A, Mazzolini M, Kantar A. A reappraisal of the mucoactive activity and clinical efficacy of bromhexine. Multidiscip Respir Med. 2017;12(1):1-14.10.1186/s40248-017-0088-1535981728331610"
}
],
"reference-count": 26,
"references-count": 26,
"relation": {},
"resource": {
"primary": {
"URL": "https://www.sciendo.com/article/10.2478/cipms-2022-0020"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Pharmacology",
"Molecular Biology",
"General Medicine",
"Biochemistry"
],
"subtitle": [],
"title": "Pharmacotherapy prescribing pattern and outcome for hospitalized patients with severe and critical COVID-19",
"type": "journal-article",
"volume": "0"
}
